Fieldview Capital Management LLC Buys Shares of 1,081 United Therapeutics Corporation $UTHR

Fieldview Capital Management LLC bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 1,081 shares of the biotechnology company’s stock, valued at approximately $527,000.

Several other large investors also recently bought and sold shares of the company. Darwin Global Management Ltd. acquired a new stake in United Therapeutics in the third quarter valued at $317,617,000. Norges Bank acquired a new stake in United Therapeutics in the fourth quarter valued at $293,418,000. Dimensional Fund Advisors LP grew its holdings in United Therapeutics by 3.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 528,210 shares of the biotechnology company’s stock valued at $257,405,000 after purchasing an additional 15,394 shares during the last quarter. Baillie Gifford & Co. acquired a new stake in United Therapeutics in the fourth quarter valued at $157,390,000. Finally, Victory Capital Management Inc. grew its holdings in United Therapeutics by 108.1% in the fourth quarter. Victory Capital Management Inc. now owns 228,383 shares of the biotechnology company’s stock valued at $111,280,000 after purchasing an additional 118,628 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of several research reports. Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective on the stock. Bank of America upped their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday. Finally, Oppenheimer upped their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Trading Up 0.7%

NASDAQ UTHR opened at $549.57 on Tuesday. The business’s 50-day moving average price is $566.45 and its 200 day moving average price is $522.10. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The company has a market capitalization of $23.33 billion, a PE ratio of 20.29, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter last year, the company posted $6.63 earnings per share. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. Equities analysts predict that United Therapeutics Corporation will post 26.84 EPS for the current year.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $9,956,712.48. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 634,468 shares of company stock valued at $357,970,302. Company insiders own 8.60% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.